Want to see OFIX full AI Analyst Report?
OFIX Stock Chart & Stats
$11.25
$0.29(2.65%)
At close: 4:00 PM EDT
$11.25
$0.29(2.65%)
Day’s Range― - ―
52-Week Range$8.85 - $16.99
Previous Close$11.25
Volume238.98K
Average Volume (3M)212.06K
Market Cap
$476.98M
Enterprise Value$605.35
Total Cash (Recent Filing)$120.28M
Total Debt (Recent Filing)$234.39M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 05, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding40,421,654
10 Day Avg. Volume220,565
30 Day Avg. Volume212,061
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.34
Price to Sales (P/S)0.74
P/FCF Ratio-472.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.50Price Target Upside37.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$843.31M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Margin ExpansionOrthofix’s $825M TTM revenue, accelerating growth and high gross margins (~69%) with positive operating cash flow show the business is generating scale and improving unit economics. That combination supports sustainable reinvestment in sales and R&D and underpins multi‑quarter margin improvement potential.
Product Pipeline & LaunchesA clear cadence of product introductions (VIRATA full‑market H2, TrueLok Elevate, Fitbone, 7D FLASH) strengthens long‑term growth levers. New offerings expand addressable markets, improve clinical differentiation, and can shift sales mix toward higher‑margin products over multiple quarters.
Reimbursement Clarity (Medicare)CMS’s July 1 reversal restores expected Medicare reimbursement for key bone‑growth HCPCS codes, removing a major payor overhang. Restored billing stability materially improves revenue visibility for stimulators and reduces structural policy risk to procedure volumes and provider purchasing decisions over coming quarters.
Bears Say
Negative ProfitabilityDespite revenue scale and margin upticks, Orthofix has not yet converted growth into consistent profits. Negative net and EBIT margins erode returns on capital and limit retained earnings, constraining the company’s ability to self‑fund strategic initiatives without relying on improved execution or external financing.
Weak Free Cash Flow ConversionOperating cash flow recovery is encouraging, but TTM free cash flow remains marginally negative. Durable cash generation is required to fund product launches and reduce leverage; continued weak FCF risks dependence on credit facilities or equity for reinvestment and heightens exposure to any adverse demand shocks.
Portfolio Underperformance & Operational HeadwindsPersistent softness in biologics and flat U.S. limb reconstruction limit revenue diversification and compress near‑term growth. Combined with prior distributor/product transitions, these franchise issues can delay margin recovery and require sustained commercial remediation to restore multi‑quarter growth trends.
Orthofix Medical News
OFIX FAQ
What was Orthofix Medical’s price range in the past 12 months?
Orthofix Medical lowest stock price was $8.85 and its highest was $16.99 in the past 12 months.
What is Orthofix Medical’s market cap?
Orthofix Medical’s market cap is $476.98M.
When is Orthofix Medical’s upcoming earnings report date?
Orthofix Medical’s upcoming earnings report date is Aug 05, 2026 which is today.
How were Orthofix Medical’s earnings last quarter?
Currently, no data Available
Is Orthofix Medical overvalued?
According to Wall Street analysts Orthofix Medical’s price is currently Undervalued.
Does Orthofix Medical pay dividends?
Orthofix Medical does not currently pay dividends.
What is Orthofix Medical’s EPS estimate?
Orthofix Medical’s EPS estimate is -0.41.
How many shares outstanding does Orthofix Medical have?
Orthofix Medical has 40,421,654 shares outstanding.
What happened to Orthofix Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Orthofix Medical?
Currently, no hedge funds are holding shares in OFIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthofix Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (37.78% Upside)
$15.50 (37.78% Upside)
Blogger Sentiment
Neutral
OFIX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 30.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.71%
Trailing 12-Months
Company Description
Orthofix Medical
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
OFIX Company Deck
OFIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed steady, disciplined execution with several clear operational and commercial positives: modest top-line growth in Q1, strong performance among top distributors, outperformance in Therapeutic Solutions, improving gross margin, a healthy innovation pipeline (7D, TrueLok Elevate, Fitbone, VIRATA) and reaffirmed full-year guidance. At the same time, challenges persist—Biologics remains soft, U.S. Limb Reconstruction growth was flat, absolute EBITDA was modest, and some results were influenced by timing, mix and prior commercial transitions. Management emphasized that distributor transitions are largely behind them and discussed focused leadership changes and product launches to drive acceleration through the year. Overall, the positives and negatives are balanced, with evidence of improving momentum but meaningful operational work still required.View all OFIX earnings summariesOFIX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$15.50
▲(37.78% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
25.94% Insiders
12.58% Mutual Funds
0.26% Other Institutional Investors
47.74% Public Companies and
Individual Investors








